Robert II - Arcus Biosciences Principal CFO
| RCUS Stock | USD 15.50 0.04 0.26% |
Insider
Robert II is Principal CFO of Arcus Biosciences
| Age | 51 |
| Address | 3928 Point Eden Way, Hayward, CA, United States, 94545 |
| Phone | 510 694 6200 |
| Web | https://www.arcusbio.com |
Arcus Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.1525) % which means that it has lost $0.1525 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4977) %, meaning that it created substantial loss on money invested by shareholders. Arcus Biosciences' management efficiency ratios could be used to measure how well Arcus Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.29 in 2024. Return On Capital Employed is likely to drop to -0.39 in 2024. At this time, Arcus Biosciences' Net Tangible Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 113 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 211.7 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Richard MD | X4 Pharmaceuticals | 61 | |
| Mary DiBiase | X4 Pharmaceuticals | 63 | |
| Ruhi MBA | Caribou Biosciences | 49 | |
| Reinhard Kandera | Hookipa Pharma | 55 | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| Mark DVM | Fate Therapeutics | 63 | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| MS MBA | Fate Therapeutics | N/A | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| Cindy Hayashi | Caribou Biosciences | N/A | |
| RPh RPh | Karyopharm Therapeutics | 55 | |
| YuWaye MD | Fate Therapeutics | N/A | |
| Rachel Haurwitz | Caribou Biosciences | 38 | |
| Syed MD | Caribou Biosciences | 57 | |
| Justin Skoble | Caribou Biosciences | N/A | |
| Klaus Orlinger | Hookipa Pharma | 46 | |
| James JD | Karyopharm Therapeutics | N/A | |
| Joern Aldag | Hookipa Pharma | 65 | |
| Jason MBA | Caribou Biosciences | 56 | |
| Steven Kanner | Caribou Biosciences | 65 | |
| Sharon MBA | Karyopharm Therapeutics | 54 | |
Management Performance
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.15 |
Arcus Biosciences Leadership Team
Elected by the shareholders, the Arcus Biosciences' board of directors comprises two types of representatives: Arcus Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arcus. The board's role is to monitor Arcus Biosciences' management team and ensure that shareholders' interests are well served. Arcus Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arcus Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer MBA, Chief Officer | ||
| Juan Jaen, President, Co-Founder, Director | ||
| Nicole Lambert, Director | ||
| Patrick Machado, Independent Director | ||
| Jason Barker, Vice President - Finance | ||
| Jennifer Jarrett, Chief Business and Financial Officer | ||
| Michael Quigley, Director | ||
| Linda Higgins, Director | ||
| Alexander Azoy, VP Officer | ||
| Antoni Ribas, Independent Director | ||
| Holli Kolkey, Vice Communications | ||
| Carolyn JD, General Secretary | ||
| Katherine Bock, Vice Strategy | ||
| Andrew Perlman, Independent Director | ||
| Robert II, Principal CFO | ||
| Eric Hoefer, Chief Commercial Officer & Head of Business Development | ||
| Stephen Young, Senior Biology | ||
| Jonathan Yingling, Chief Officer | ||
| Terry Rosen, Chairman of the Board, Chief Executive Officer, Co-Founder | ||
| Yvonne Gehring, Senior Operations | ||
| Alexander CPA, VP Officer | ||
| Robert Goeltz, Chief Financial Officer, Principal Financial and Accounting Officer | ||
| Yasunori Kaneko, Lead Independent Director | ||
| David Lacey, Independent Director | ||
| Kathryn Falberg, Independent Director | ||
| Carolyn Tang, General Counsel | ||
| Merdad Parsey, Director | ||
| Christopher Garcia, CoFounder Board | ||
| William Grossman, Chief Medical Officer | ||
| Pia Eaves, Vice Strategy |
Arcus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arcus Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.03) % | ||||
| Operating Margin | (2.19) % | ||||
| Current Valuation | 387.43 M | ||||
| Shares Outstanding | 91.51 M | ||||
| Shares Owned By Insiders | 38.80 % | ||||
| Shares Owned By Institutions | 60.07 % | ||||
| Number Of Shares Shorted | 8.03 M | ||||
| Price To Earning | 27.69 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.